Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for this Phase 2 prostate cancer trial is displayed, including its treatment arms, eligibility criteria, outcome measures, study dates, and protocol document.
    Difference
    75%
    Check dated 2026-11-08T13:51:52.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0; the study record remains inaccessible with a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:13:11.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces transition updates and says NIH content may use “Super Intelligence” instead of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-25T14:24:28.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision number changed from v3.7.1 to v3.7.2; the study page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T15:26:35.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.0 to v3.7.1, while the study record remains inaccessible behind a 403 error.
    Difference
    0.2%
    Check dated 2026-10-11T15:17:48.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record details. This replaces the trial information with an access-denied screen.
    Difference
    22%
    Check dated 2026-09-20T20:35:07.000Z thumbnail image

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.